8-K: Alkermes Reports Q2 2026 Results, CEO Transition

Alkermes plc announced its second quarter 2026 financial results, reporting $496.0 million in revenue and $139.2 million in Adjusted EBITDA, while also announcing a CEO transition effective August 1, 2026.

Summary

• Alkermes plc reported second quarter 2026 financial results, with total revenues of $496.0 million, an increase from $390.7 million in the prior year's second quarter.
• Proprietary net sales reached $411.7 million, driven by strong performance in VIVITROL ($124.5 million), ARISTADAi ($96.7 million), LYBALVI ($94.0 million), and LUMRYZ ($96.6 million).
• The company reported GAAP Net Income of $0.5 million for the quarter, compared to $87.1 million in Q2 2025, and Adjusted EBITDA of $139.2 million, up from $126.5 million in Q2 2025.
• For the six months ended June 30, 2026, total revenues were $888.9 million, and the company reported a GAAP Net Loss of $66.0 million.
• The company updated its full-year 2026 financial expectations, projecting total revenues between $1,730 million and $1,840 million.
• Blair Jackson is set to assume the role of Chief Executive Officer on August 1, 2026, with Richard Pops continuing as Chairman of the Board.
• Pipeline updates include expected ADHD data for ALKS 7290 in the coming months and topline results from the alixorexton phase 2 idiopathic hypersomnia study by year-end.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While revenue and Adjusted EBITDA show year-over-year growth, the significant decline in GAAP Net Income and the worsening of full-year GAAP Net Loss and EBITDA guidance indicate underlying financial pressures and a less favorable outlook than previously presented.

Positives

• Total revenues increased by 27% to $496.0 million in Q2 2026 compared to $390.7 million in Q2 2025.
• Proprietary net sales grew significantly to $411.7 million in Q2 2026 from $307.2 million in Q2 2025.
• LYBALVI revenues increased 12% and total prescriptions grew 18% compared to the second quarter of 2025.
• Adjusted EBITDA increased to $139.2 million in Q2 2026 from $126.5 million in Q2 2025.
• Cash, cash equivalents, and total investments increased to $691.6 million at June 30, 2026, from $538.2 million at March 31, 2026.
• Updated full-year 2026 revenue guidance remains strong, with the upper end of the range at $1,840 million.
• Positive topline results from the LUMRYZ phase 3 study in idiopathic hypersomnia were announced, impacting contingent consideration.

Negatives

• GAAP Net Income decreased significantly to $0.5 million in Q2 2026 from $87.1 million in Q2 2025.
• GAAP Net Loss for the six months ended June 30, 2026, was $66.0 million, compared to a Net Income of $109.6 million for the same period in 2025.
• EBITDA decreased to $49.0 million in Q2 2026 from $101.6 million in Q2 2025.
• Updated full-year 2026 GAAP Net Loss is projected to be between ($95) million and ($115) million, a wider loss than previously expected.
• Updated full-year 2026 EBITDA is projected to be between $75 million and $95 million, a decrease from previous expectations.
• Updated full-year 2026 Adjusted EBITDA guidance remains unchanged, but the GAAP Net Loss projection has worsened.

Risks

• Potential for unfavorable outcomes in arbitration, litigation, or other proceedings related to products.
• Regulatory authorities may make adverse decisions regarding products.
• Inability to continue successfully commercializing products or support revenue growth.
• Changes in the competitive landscape, including earlier than anticipated generic competition.
• Potential changes in the cost, scope, design, or duration of development programs.
• Results of development activities may not be positive or predictive of final results.
• Risks associated with the integration of the Avadel acquisition and achievement of expected benefits.
• Unknown or inestimable liabilities and potential litigation associated with the acquisition.

Future Outlook

The company updated its financial expectations for the year ending December 31, 2026, projecting total revenues between $1,730 million and $1,840 million. The projected GAAP Net Loss is now expected to be between ($95) million and ($115) million, and projected EBITDA is expected to be between $75 million and $95 million. Key pipeline milestones include ADHD data for ALKS 7290 in the coming months and topline results from the alixorexton phase 2 idiopathic hypersomnia study by year-end.

Management Comments

• "Our commercial portfolio consists of differentiated products that are positioned to generate substantial revenue and cash flow for years to come. At the same time, our orexin 2 receptor agonist portfolio represents a potentially transformational growth opportunity for Alkermes and positions us at the forefront of one of the most exciting new therapeutic categories in neuroscience."
• "As I prepare to transition the Chief Executive Officer role, I do so with tremendous pride in what this organization has achieved and great optimism for its future. Blair and the leadership team are well positioned to build on this momentum and lead Alkermes through its next phase of growth, innovation and value creation, and I look forward to supporting them in my continuing role as Chairman."
• "As we move into the second half of the year, we have clear priorities and a sharp focus on execution. With our first ADHD data for ALKS 7290 expected in the coming months and topline results from our alixorexton phase 2 idiopathic hypersomnia study expected toward year-end, we are generating significant new datasets that may open new opportunities for our orexin 2 receptor portfolio."
• "With a talented team, a strong financial foundation and exciting opportunities ahead in sleep medicine and across our neuroscience portfolio, I am honored to step into the CEO role and continue building on the strong foundation for growth that Richard and the entire organization have established."

Industry Context

StockSavvy.ai notes that Alkermes' focus on neuroscience, particularly its orexin 2 receptor agonist portfolio for conditions like narcolepsy and idiopathic hypersomnia, aligns with a growing interest in novel treatments for sleep disorders and other neurological conditions. The company's strategic shift and pipeline development in this area position it within a competitive but high-potential segment of the biopharmaceutical industry.

Comparison to Industry Standards

• No direct comparisons to specific industry benchmarks or competitors were provided in the filing for Q2 2026 financial performance.
• The company's revenue growth in proprietary products is a positive indicator, but direct comparison to peers requires further market analysis.
• The updated full-year guidance for GAAP Net Loss and EBITDA indicates a potential divergence from industry standards for profitability, especially considering the impact of acquisition-related costs and R&D investments.

Management Changes

Legal Proceedings

• Potential for arbitration, litigation, or other proceedings or disputes related to the company's products or technologies.

Stakeholder Impact

• Shareholders may react to the decreased GAAP profitability and revised full-year guidance, potentially impacting stock price.
• Employees will experience a leadership transition with Blair Jackson taking over as CEO.
• Customers and suppliers are likely to be unaffected in the short term, but long-term strategic shifts could have implications.

Next Steps

• ALKS 7290 ADHD data expected in the coming months.
• Topline results from alixorexton phase 2 idiopathic hypersomnia study expected toward year-end.
• Blair Jackson to assume CEO role on August 1, 2026.
• Company to continue executing on strategic priorities and pipeline development.

Key Dates

Recommendation

The company shows strong revenue growth and positive pipeline developments, but the significant decrease in GAAP profitability and the downward revision of full-year guidance for GAAP Net Loss and EBITDA warrant a cautious approach. The CEO transition adds another layer of uncertainty. A 'hold' recommendation reflects the balance between positive commercial and pipeline momentum and the concerning financial performance trends and revised outlook.

Keywords

Alkermes, Q2 2026, Financial Results, Revenue, EBITDA, Neuroscience, Biopharmaceutical, CEO Transition